cellprotect.se
About company
CellProtect Nordic Pharmaceuticals AB has developed an IP-protected process for GMP manufacturing of the NK-cell based drug candidate CellProtect for treatment of multiple myeloma. There are solid preclinical data showing that NK-cells expanded with the patented technology have restored cytotoxic activity and ability to selectively kill myeloma tumour cells. A Phase I / II clinical trial in multiple myeloma patients has been performed where CellProtect has been studied as an adjunct therapy to autologous stem cell transplantation. The results are very promising and CellProtect in the clinical trials shows a good safety profile. CellProtect was recently granted orphan drug designation from the European Commission for the treatment of multiple myeloma.
